Tumor neoantigen-specific T cell response induction

The term "Tumor neoantigen-specific T cell response induction" does not refer to a single molecular target, receptor, or protein. Instead, it describes the **immunological process** by which the immune system—specifically **T cells**—recognizes and responds to tumor-derived neoantigens. Neoantigens are novel peptides generated from non-synonymous mutations in tumor DNA that are presented on major histocompatibility complex (MHC) molecules and recognized as 'non-self' by the host's immune system[1][2][3]. This recognition can lead to activation of both **CD8+ cytotoxic** and **CD4+ helper** T cells that mediate antitumor effects. Neoantigen-specific T cell responses are central to several cancer immunotherapies—including checkpoint inhibitors and personalized cancer vaccines—but this entry is not itself a druggable target like a receptor or enzyme[1][2]. Rather, it is an outcome or goal of certain therapies aiming to harness or boost these specific immune responses for therapeutic benefit. Because this entry refers to an immunological phenomenon rather than a discrete molecular entity, it should not be classified as a canonical therapeutic target. There is nothing misspelled about the phrase itself; however, its use as a "target" in structured databases would be incorrect since it does not correspond to any single gene product or druggable molecule.

Other names

Neoantigen-specific T cell responseTumor neoantigen-specific T cell immunityNeoantigen-reactive T cells